We have recently identified PTGDRs as promising therapeutic targets by assessing, successfully, the efficacy of the combination of two single antagonists, one targeting PTGDR-1 (laropiprant) and the other targeting PTGDR-2 (CAY10471), in ameliorating the autoimmune and renal parameters in lupus-like disease and the importance of the PGD2 axis in the pathogenesis of lupus (10). Here, PTGDR is linked to systemic lupus erythematosus.